Between December 8 and December 10, 2025, SNY faced a series of analyst rating adjustments that tempered investor sentiment.

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...

Federal regulators have begun a safety review of 2 RSV medicines used to protect infants, even though no safety problems have been reported.

U.S. regulators launch new review of infant RSV therapies from Merck, Sanofi, and AstraZeneca amid scrutiny by Health Secretary Robert F. Kennedy Jr.

Sanofi ( ($SNY) ) just unveiled an update. In December 2025, Sanofi announced the completion of its acquisition of Vicebio Ltd, which enhances its ...

Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

Federal officials say the U.S. Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and ...

On the campaign trail last October, President Trump promised to let his health secretary, Robert F. Kennedy Jr., “go wild on ...

RSV vaccines were 58% effective at preventing RSV-associated hospitalizations among adults age 60 or older across two seasons. Vaccine effectiveness against all-cause cardiorespiratory ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...